Population Pharmacokinetics of Intravenous Isavuconazole in Solid Organ Transplant Recipients.
Isavuconazole (ISA) is a triazole antifungal with anti-yeast and anti-mould activity. We established a population pharmacokinetic (pop PK) model of intravenous (IV) ISA to identify covariates that affect pharmacokinetics, using plasma samples from solid organ transplant (SOT) recipients receiving peri-transplant prophylaxis. Samples (n=471) from 79 SOT recipients were utilized for pop PK analysis using nonlinear mixed effect modelling NONMEM® software. IV ISA PK parameters were best described by a two-compartment model. Significant covariates were the impact of sex on clearance (∼53% higher in women than men) and increased body mass index on increased peripheral volume of distribution. Incorporating drug exposure into Monte Carlo simulations, we demonstrated that standard ISA dosing is likely to attain the PK-pharmacodynamic (PD) target (area under the concentration curve/minimum inhibitory concentration ratio (AUC/MIC)) for treatment effectiveness against almost all infections caused by A. fumigatus exhibiting MICs ⩽0.5 μg/mL (modal MIC). In contrast, standard dosing is predicted to attain PK-PD targets against <20% of infections caused by C. albicans or C. glabrata exhibiting MICs ⩾0.016 and ⩾0.5 μg/mL, respectively (modal MICs). These data are consistent with our SOT program's experience with ISA breakthrough infections, 3 of 4 of which were caused by C. glabrata for which probabilities of PK-PD target attainment (PTA) were only 70% and 0% for isolates with MIC=0.25 μg/mL and 1 μg/mL. Our findings provide important new insights into how ISA use might be optimized following SOT.